Seroprevalence of nine human papillomavirus types included in the nonavalent vaccine in unvaccinated women living in Puerto Rico: A population-based study
Year: 2025
Type: article
Study design: Observational Study
Abstract: OBJECTIVES: To estimate the seroprevalence of human papillomavirus (HPV) types included in the nonavalent HPV (9vHPV) vaccine among unvaccinated women and determine factors associated with seropositivity. METHODOLOGY: Data from a population-based cross-sectional study of HPV infection among sexually active women (16-64 years) conducted in Puerto Rico from 2010 to 2013 was assessed (n = 524). Antibody responses to 9vHPV types (HPV-6/11/16/18/31/33/45/52/58) were analyzed using M9ELISA by the United States Centers for Disease Control and Prevention. Age-adjusted prevalence odds ratios (aPOR) were estimated with 95% confidence intervals (CI). RESULTS: The mean participant age was 42.4 ± 0.6 years; 69.2% were seropositive to ≥1 of the 9vHPV types and 0.5% to all types. Women who had their sexual debut at ≥18 years old (aPOR: 0.4, 95% CI: 0.2-0.8) had lower odds of seropositivity to any 9vHPV types compared to those with a younger sexual debut age. Higher odds of seropositivity were observed among women with 3-9 (aPOR: 4.4, 95% CI: 1.9-10.2) and with ≥10 (aPOR: 4.3, 95% CI: 1.5-12.6) lifetime sexual partners, and women with a history of an abnormal Pap test result (aPOR: 2.5, 95% CI: 1.1-5.6) compared to their counterparts. CONCLUSION: The high seroprevalence of 9vHPV types found in our study underscores the potential benefits of following the recommended vaccine schedule to reduce HPV and cervical cancer burden in this population.
Authors: A. Cruz, J.M. Ramos-Cartagena, G. Panicker, C.M. Pérez, E. Suárez, J. Romaguera, E.R. Unger, T. Rivera, A.P. Ortiz
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,900
Funders: National Institutes of Health, Centers for Disease Control and Prevention, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, National Institute on Minority Health and Health Disparities, Division of Cancer Epidemiology and Genetics, National Cancer Institute
Awards: G1869017074, Anogenital HPV Infection in a Population-Based Sample of Puerto Rican Women, G5796175702, G703352663, Puerto Rico Clinical and Translational Research Consortium, G8317889825, G9000193316, The effectiveness, cost-effectiveness, and budget impact of interventions to improve the delivery of cervical cancer screening in Puerto Rico.
OpenAlex ID: W4416202813